Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities

Abstract

Aim: Efficient and readily available anticancer drugs are sought as treatment options. For this reason, chromene derivatives were prepared using the one-pot reaction and tested for their anticancer and anti-angiogenic properties.

Methods: 2-Amino-3-cyano-4-(aryl)-7-methoxy-4H-chromene compounds (2A-R) were repurposed or newly synthesized via a three-component reaction of 3-methoxyphenol, various aryl aldehydes, and malononitrile. We performed assays to study the inhibition of tumor cell growth [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromid (MTT) assay], effects on microtubules (immunofluorescence), cell cycle (flow-activated cell sorting analysis), angiogenesis (zebrafish model), and MYB activity (luciferase reporter assay). Fluorescence microscopy was applied for localization studies via copper-catalyzed azide-alkyne click reaction of an alkyne-tagged drug derivative.

Results: Compounds 2A-C and 2F exhibited robust antiproliferative activities against several human cancer cell lines (50% inhibitory concentrations in the low nanomolar range) and showed potent MYB inhibition. The alkyne derivative 3 was localized in the cytoplasm after only 10 min of incubation. Substantial microtubule disruption and G2/M cell-cycle arrest were observed, where compound 2F stood out as a promising microtubule-disrupting agent. The study of anti-angiogenic properties showed that 2A was the only candidate with a high potential to inhibit blood vessel formation in vivo.

Conclusion: The close interplay of various mechanisms, including cell-cycle arrest, MYB inhibition, and anti-angiogenic activity, led to identifying promising multimodal anticancer drug candidates.

Keywords

Chromene / pyran / anticancer drugs / microtubule / angiogenesis / MYB inhibition

References

[1] Fouad MA,Ayoup MS.Two decades of recent advances of Ugi reactions: synthetic and pharmaceutical applications.RSC Adv2020;10:42644-81 PMCID:PMC9058431

[2] Nagarajaiah H,Moorthy JN.Biginelli reaction: an overview.Tetrahedron Lett2016;57:5135-49

[3] Zheng X,Zhang D.Recent advances in the synthesis of oxazole-based molecules via van leusen oxazole synthesis.Molecules2020;25:1594 PMCID:PMC7180750

[4] Wang L,Li Q.Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.J Med Chem2002;45:1697-711

[5] Kemnitzer W,Jiang S.Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions.Bioorg Med Chem Lett2005;15:4745-51

[6] Kemnitzer W,Jiang S.Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions.J Med Chem2007;50:2858-64

[7] Schmitt F,Rothemund M.New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents.Eur J Med Chem2019;163:160-8

[8] Schmitt F,Biersack B.New pyranoquinoline derivatives as vascular-disrupting anticancer agents.Med Chem Res2019;28:1694-703

[9] Dell CP,Smith CW. Pharmaceutical Compounds. Pat. No. US005284868 A (1994).

[10] Wood DL,Wiernicki TR,Jordan MA.Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181.Mol Pharmacol1997;52:437-44

[11] Yusenko MV,Frank D.Bcr-TMP, a novel nanomolar-active compound that exhibits both MYB- and microtubule-inhibitory activity.Cancers (Basel)2021;14:43 PMCID:PMC8750090

[12] Cicirò Y.MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.Oncogenesis2021;10:19 PMCID:PMC7910556

[13] Köhler LHF,Begemann G,Biersack B.2-Amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles with microtubule-disruptive, centrosome-declustering, and antiangiogenic effects in vitro and in vitro.ChemMedChem2022;17:e202200064 PMCID:PMC9311119

[14] Cai SX,Jiang S. Preparation of substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and their uses against cancer and other disorders. Pat. No. WO2002092594 (2002).

[15] Grossman D.Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.Cancer Metast Rev2001;20:3-11

[16] Lawson ND.In vivo imaging of embryonic vascular development using transgenic zebrafish.Dev Biol2002;248:307-18

[17] Chayka O,Braas D.v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter.Mol Cell Biol2005;25:499-511 PMCID:PMC538795

[18] Yusenko M,Klempnauer KH.A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.Sci Rep2018;8:13159 PMCID:PMC6120916

[19] Lau VM,Markland TE.Electrostatic control of regioselectivity in Au(I)-catalyzed hydroarylation.J Am Chem Soc2017;139:4035-41

[20] Köhler LHF,Yusenko M.A new naphthopyran derivative combines c-myb inhibition, microtubule-targeting effects, and antiangiogenic properties.ACS Med Chem Lett2022;13:1783-90 PMCID:PMC9661705

[21] Verschraagen M,Schellens JH.P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.Pharmacol Res1999;40:301-6

[22] Biersack B,Schobert R.Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles.Bioorg Med Chem Lett2011;21:6270-3

[23] Schwartz EL.Antivascular actions of microtubule-binding drugs.Clin Cancer Res2009;15:2594-601 PMCID:PMC2745203

[24] Arnaoutova I.In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract.Nat Protoc2010;5:628-35

[25] Cross LM,Lin S,Rubinstein AL.Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay.Arterioscler Thromb Vasc Biol2003;23:911-2

[26] Choueiri TK.Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.Curr Opin Pharmacol2008;9:658-71

[27] Gao X,Board M.Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer.Biochim Biophys Acta Gen Subj2021;1865:129915

[28] Yanase K,Asada S,Imai Y.Gefitinib reverses breast cancer resistance protein-mediated drug resistance.Mol Cancer Ther2004;3:1119-25

[29] Leggas M,Zhuang Y.Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.Cancer Res2006;66:4802-7

[30] Sharom FJ.The P-glycoprotein multidrug transporter.Essays Biochem2011;50:161-78

[31] Scala S,Rao US.P-glycoprotein substrates and antagonists cluster into two distinct groups.Mol Pharmacol1997;51:1024-33

[32] Lei ZN,Wu ZX.Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells.MedComm2021;2:765-77 PMCID:PMC8706751

[33] Su M,Liu S.The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4.Sci Rep2016;6:28139 PMCID:PMC4919637

[34] Anfossi G,Calabretta B.An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines.Proc Natl Acad Sci USA1989;86:3379-83 PMCID:PMC287136

[35] Calabretta B,Valtieri M.Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.Proc Natl Acad Sci USA1991;88:2351-5 PMCID:PMC51229

[36] Guérin M,Andrieu N.Strong association between c-myb and oestrogen-receptor expression in human breast cancer.Oncogene1990;5:131-5

[37] Drabsch Y,Zhang R.Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells.Proc Natl Acad Sci USA2007;104:13762-7 PMCID:PMC1959456

[38] Biroccio A,D’agnano I.c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer.Am J Pathol2001;158:1289-99 PMCID:PMC1891926

[39] Hugo H,Suraweera N.Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers.Gene Chromosome Canc2006;45:1143-54

[40] Degirmenci U,Sim YRM,Hu J.Drug resistance in targeted cancer therapies with RAF inhibitors.Cancer Drug Resist2021;4:665-83 PMCID:PMC9094075

[41] Li Y,Cheng H.Discovery of BRAF/HDAC dual inhibitors suppressing proliferation of human colorectal cancer cells.Front Chem2022;10:910353 PMCID:PMC9354042